Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-Associated hypercoagulation

Colin E. Evans, Pär Ola Bendahl, Mattias Belting, Cristina Branco, Randall S. Johnson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Despite the increased risk of thrombosis in cancer patients compared with healthy individuals, mechanisms that regulate cancer-induced hypercoagulation are incompletely understood. The aim of this study was to investigate whether cell-specific hypoxia-inducible factor (HIF) 1α regulates cancer-associated hypercoagulation, using in vitro clotting assays and in vivo cancer models. In mouse lung and mammary tumor cells, hypoxia led to increases in cell adhesion, clotting, and fibrin deposition; these increases were eliminated in HIF1α null cells. Increased levels of HIF1α were also associated with increased tissue factor expression in human breast tumor samples. Conversely, deletion of endothelial (but not myeloid) cell-specific HIF1α doubled pulmonary fibrin deposition, and trebled thrombus formation compared with wildtype littermates in tumor-bearing mice. Our data suggest that tumor and endothelial cell-specific HIF1α may have opposing roles in cancer-associated coagulation and thrombosis. Off-target effects of manipulating the HIF1 axis in cancer patients should be carefully considered when managing thrombotic complications.
Original languageEnglish
Pages (from-to)1355-1360
JournalBlood
Volume127
Issue number10
DOIs
Publication statusPublished - 10 Mar 2016

Fingerprint Dive into the research topics of 'Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-Associated hypercoagulation'. Together they form a unique fingerprint.

  • Cite this